Neoplastic Meningitis

Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996;53:626–632.PubMedGoogle Scholar

Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289: 770–773.PubMedGoogle Scholar

Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979;6:207–213.PubMedCrossRefGoogle Scholar

Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998;82:1756–1763.PubMedCrossRefGoogle Scholar

Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991;67: 1685–1695.PubMedCrossRefGoogle Scholar

Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997;87:694–699.PubMedCrossRefGoogle Scholar

Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M. ¹¹¹Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999;52:216–217.PubMedGoogle Scholar

Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77:1315–1323.PubMedCrossRefGoogle Scholar

Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998a;82:733–739.PubMedCrossRefGoogle Scholar

Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998b;16:1561–1567.PubMedGoogle Scholar

Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995;75:2919–2931.PubMedCrossRefGoogle Scholar

Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999a;5:3394–3402.PubMedGoogle Scholar

Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999b;17:3110–3116.PubMedGoogle Scholar

Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979;29:1369–1375.PubMedGoogle Scholar

Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11:561–569.PubMedGoogle Scholar

Hitchins RN, Bell DR, Woods RL, Levi JA, A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655–1662.PubMedGoogle Scholar

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Version 2.2006. Central Nervous System Cancers. National Comprehensive Cancer Network; 2006.Google Scholar

Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974;30:122–137.PubMedGoogle Scholar

Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases—treatment results in 98 consecutive patients. Isr J Med Sci 1988;24:611–618.PubMedGoogle Scholar

Posner JB. Leptomeningeal metastases. In: Posner JB, ed. Neurologic Complications of Cancer. Philadelphia, PA: F.A. Davis; 1995:143–171.Google Scholar

Stewart DJ, Maroun JA, Hugenholtz H, et al. Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies. J Neurooncol 1987;5:315–322.PubMedCrossRefGoogle Scholar

Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49: 759–772.PubMedCrossRefGoogle Scholar